174885-99-5

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINO-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of pharmaceutical compounds for its versatile chemical properties and potential therapeutic applications.
Used in Antifungal Applications:
(2-AMINO-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an antifungal agent due to its ability to combat fungal infections, making it a potential candidate for the development of new therapeutic agents.
Used in Antibacterial Applications:
(2-AMINO-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an antibacterial agent for its capacity to inhibit bacterial growth, contributing to the development of new treatments for bacterial infections.
Used in Neurodegenerative Disease Treatment:
(2-AMINO-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used in research for the treatment of neurodegenerative diseases, given its potential neuroprotective properties and ability to mitigate disease progression.
Used in Anti-inflammatory Applications:
(2-AMINO-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an anti-inflammatory agent, leveraging its capacity to reduce inflammation and alleviate symptoms associated with inflammatory conditions.

InChI:InChI=1/C13H20N2O2/c1-13(2,3)17-12(16)15-9-11(14)10-7-5-4-6-8-10/h4-8,11H,9,14H2,1-3H3,(H,15,16)

Upstream product

• 912762-45-9 C₁₃H₁₈N₂O₃ 
• 76477-26-4 (2-Oxo-2-phenylethyl)carbamic acid tert-butyl ester 
• 613-89-8 2-Aminoacetophenone 
• 70-11-1 α-bromoacetophenone 
• 7568-93-6 2-Amino-1-phenylethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67341-07-5 tert-butyl N-(2-hydroxy-2-phenylethyl)carbamate 
• 943321-52-6 tert-butyl 2-(1,3-dioxoisoindolin-2-yl)-2-phenylethylcarbamate 

Downstream Products

• 943323-02-2 1,1-dimethylethyl (2-{[(5-bromo-2-thienyl)methyl]amino}-2-phenylethyl)carbamate 
• 943321-53-7 1,1-dimethylethyl (2-{[(5-bromo-2-thienyl)carbonyl]amino}-2-phenylethyl)carbamate 
• 1044851-72-0 1,1-dimethylethyl (2-{[(5-bromo-3-thienyl)carbonyl]amino}-2-phenylethyl)carbamate 
• 943323-27-1 1,1-dimethylethyl (2-{[(4,5-dibromo-2-thienyl)carbonyl]amino}-2-phenylethyl)carbamate 
• 1387641-22-6 7-Methoxy-6-(2-methoxy-ethoxy)-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid [5-(2-amino-1-phenyl-ethylcarbamoyl)-2-methyl-phenyl]-amide 
• 1387641-17-9 6,7-dimethoxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid [5-(2-amino-1-phenyl-ethylcarbamoyl)-2-methyl-phenyl]-amide 
• 1386981-70-9 tert-butyl 2-(4-chloro-3-(2-methoxy-4-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamido)benzamido)-2-phenylethylcarbamate 
• 1386981-45-8 tert-butyl 2-(4-chloro-3-(7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamido)benzamido)-2-phenylethylcarbamate 
• 1386981-07-2 tert-butyl 2-(4-chloro-3-(2-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamido)benzamido)-2-phenylethylcarbamate 
• 1386980-84-2 (2-{4-chloro-3-[(2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonyl)-amino]-benzoylamino}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 1386979-70-9 2-methoxy-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid [5-(2-amino-1-phenyl-ethylcarbamoyl)-2-chloro-phenyl]-amide 

Relevant academic research and scientific papers

COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR

The invention relates to the field of pharmaceutical chemistry. Specifically, the present invention relates to a series of BET (bromodomain and extra-terminal domain) inhibitors having a novel structure, particularly inhibitors targeting BRD4 (Bromodomain-containing protein 4), and a preparation method and use therefor. The structure thereof is shown in the following general formula (I). Said compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate, solvate, or crystal form thereof, or a pharmaceutically acceptable salt thereof, and the pharmaceutical compsosition thereof can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.

PYRAZOLO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

PYRIDO PYRIMIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

CARBOXYLIC ACID ARYL AMIDES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

IMIDAZO PYRAZINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositio

PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

INHIBITORS OF AKT ACTIVITY

Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.